LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

Search

Twist Bioscience Corp

Slēgts

SektorsVeselības aprūpe

46.65 -4.25

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

46.3

Max

48.93

Galvenie mērījumi

By Trading Economics

Ienākumi

-3.4M

-31M

Pārdošana

4.7M

104M

Peļņas marža

-29.419

Darbinieki

979

EBITDA

-3.2M

-24M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+6.91% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 4. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

127M

2.7B

Iepriekšējā atvēršanas cena

50.9

Iepriekšējā slēgšanas cena

46.65

Ziņu noskaņojums

By Acuity

50%

50%

164 / 349 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Twist Bioscience Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 26. marts 23:43 UTC

Tirgus saruna

Nikkei May Decline Amid Uncertainty Over Iran Peace Talks -- Market Talk

2026. g. 26. marts 23:36 UTC

Tirgus saruna
Galvenie ziņu notikumi

Gold Rises Amid Signs of Easing Middle East Tensions -- Market Talk

2026. g. 26. marts 23:35 UTC

Iegādes, apvienošanās, pārņemšana

Pernod Ricard: Confirms Discussions With Brown-Forman

2026. g. 26. marts 23:29 UTC

Peļņas

Haier Smart Home: Company to Finance Share Buybacks Via Internal Funds >600690.SH

2026. g. 26. marts 23:28 UTC

Peļņas

Haier Smart Home Plans A Share Buybacks of CNY3.0B-CNY6.0B >600690.SH

2026. g. 26. marts 23:28 UTC

Peļņas

Haier Smart Home Plans to Increase Payout Ratio to 60% for 2027, 2028 >600690.SH

2026. g. 26. marts 23:28 UTC

Peļņas

Haier Smart Home Plans Cash Dividend Payout Ratio of Up to 58% for 2026 >600690.SH

2026. g. 26. marts 23:27 UTC

Peļņas

Haier Smart Home 2025 Net CNY19.55B Vs. Net CNY18.73B >600690.SH

2026. g. 26. marts 23:27 UTC

Peļņas

Haier Smart Home 2025 Rev CNY302.33B Vs. CNY286.01B >600690.SH

2026. g. 26. marts 23:08 UTC

Tirgus saruna

Infratil's Investor Day Addresses Data-Center Issues -- Market Talk

2026. g. 26. marts 23:04 UTC

Iegādes, apvienošanās, pārņemšana

Pernod Ricard in Talks to Combine With Jack Daniel's Maker Brown-Forman -- WSJ

2026. g. 26. marts 23:04 UTC

Iegādes, apvienošanās, pārņemšana

Families Behind Pernod, Brown-Forman Would Each Likely Retain Significant Stakes, Source Says -- WSJ

2026. g. 26. marts 23:04 UTC

Iegādes, apvienošanās, pārņemšana

Pernod, Brown-Forman Discussing Mostly Stock Deal, Source Says -- WSJ

2026. g. 26. marts 23:04 UTC

Iegādes, apvienošanās, pārņemšana

Pernod-Brown-Forman Deal Announcement Could Be Weeks Away, Sources Say -- WSJ

2026. g. 26. marts 23:04 UTC

Iegādes, apvienošanās, pārņemšana

Pernod in Deal Talks With Brown-Forman -- WSJ

2026. g. 26. marts 22:41 UTC

Iegādes, apvienošanās, pārņemšana

Brown-Forman: No Agreement Has Been Reached as to Terms of Any Possible Pernod Ricard Transaction

2026. g. 26. marts 22:41 UTC

Iegādes, apvienošanās, pārņemšana

Brown-Forman: Synergies From Contemplated Pernod Ricard Combination Expected to Be Significant

2026. g. 26. marts 22:26 UTC

Peļņas

Jiangxi Copper 2025 Rev CNY544.62B Vs. CNY516.61B >0358.HK

2026. g. 26. marts 22:26 UTC

Peļņas

Jiangxi Copper 2025 Net CNY7.13B Vs. Net CNY6.96B >0358.HK

2026. g. 26. marts 22:26 UTC

Peļņas

Jiangxi Copper Higher Demand For Products Supported Results>0358.HK

2026. g. 26. marts 22:08 UTC

Peļņas

Air China 2025 Loss CNY1.79B Vs. Loss CNY232.56M >0753.HK

2026. g. 26. marts 22:08 UTC

Peļņas

Air China Impairment Loss on Goodwill Weighed on Results>0753.HK

2026. g. 26. marts 22:08 UTC

Peļņas

Air China 2025 Rev CNY171.48B Vs. CNY166.70B >0753.HK

2026. g. 26. marts 22:07 UTC

Tirgus saruna
Galvenie ziņu notikumi

Global Energy Roundup: Market Talk

2026. g. 26. marts 22:07 UTC

Tirgus saruna
Galvenie ziņu notikumi

Open-Pit Gold Miners Most Exposed to High Fuel Prices -- Market Talk

2026. g. 26. marts 22:00 UTC

Peļņas

Tsingtao Brewery 2025 Net CNY4.59B Vs. Net CNY4.34B >0168.HK

2026. g. 26. marts 22:00 UTC

Peļņas

Tsingtao Brewery: Higher Volume Sales of Beer Supported Results>0168.HK

2026. g. 26. marts 22:00 UTC

Peļņas

Tsingtao Brewery 2025 Rev CNY32.47B Vs. CNY32.14B >0168.HK

2026. g. 26. marts 21:39 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope: Sees Early Indications of Strong Interest in Site Adjacent Western Port

2026. g. 26. marts 21:38 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope: Has Begun Expression of Interest Process For 65-Hectare Site Adjacent Western Port

Salīdzinājums

Cenas izmaiņa

Twist Bioscience Corp Prognoze

Cenas mērķis

By TipRanks

6.91% augšup

Prognoze 12 mēnešiem

Vidējais 52 USD  6.91%

Augstākais 58 USD

Zemākais 50 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Twist Bioscience Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

6

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

31.56 / 38.6884Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

164 / 349 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat